Journal Mobile Options
Table of Contents
Vol. 62, No. 1, 2002
Issue release date: January 2002

Expression of Cyclooxygenase-2 Is Associated with Carcinogenesis of the Lower Part of Thoracic Esophageal Squamous Cell Carcinoma and p53 Expression

Kawabe A. · Shimada Y. · Uchida S. · Maeda M. · Sato F. · Itami A. · Imamura M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Cyclooxygenase (COX) is a key enzyme in arachidonic acid metabolism. Two isoforms of this enzyme have been identified: constitutive COX-1 and inducible COX-2. Recently, expression of COX-2 has been found in several human carcinomas. COX-2 expression may contribute to the synthesis of prostanoids, which relate to carcinogenesis and tumor progression. We investigated the expression of COX-2 in 175 human esophageal squamous cell carcinoma tissues using immunohistochemistry and evaluated the relationship with clinicopathological findings. In addition, due to the known relevance of p53 to carcinogesis, we evaluated the expression of COX-2 and p53. Interestingly, cancer tissues with high COX-2 expression were found significantly more often in the middle and lower esophagus than in the cervical and upper esophagus (p = 0.0014). No significant differences were observed in other clinicopathological data such as age, sex, histopathological grading, lymphatic invasion, venous invasion, TNM clinical classification and patient prognosis. p53 expression was associated with the expression of COX-2 (p = 0.0122). Our findings suggest that COX-2 may play a role in the development of squamous cell carcinoma in the lower part of the thoracic esophagus.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322–1327.
  2. Reddy BS, Maruyama H, Kellof G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987;47:5340–5346.
  3. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 1989;157:175–179.
  4. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offenhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–1316.
  5. Miller BW, Baier LD, Morrison AR: Overexpression of protein kinase C-ζ isoform increases cyclooxygenase-2 and inducible nitric oxide synthase. Am J Physiol 1997;273:C130–C136.

    External Resources

  6. Kargman SL, O’Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556–2559.
  7. Sano H, Kawahito Y, Weilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo H, Hla T: Expression of cyclooxygenase-2 in human colorectal cancer. Cancer Res 1995;55:3785–3789.
  8. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276–1280.
  9. Dubois RN, Radhika A, Reddy BS, Entingh AJ: Increased cyclooxygenase-2 levels in carcinogen induced rat colonic tumors. Gastroenterology 1996;110:1259–1262.
  10. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996;87:803–809.
  11. Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295–315.
  12. Honn KV, Bockman RS, Marnett LJ: Prostaglandins and cancer: A review of tumor initiation through tumor metastasis. Prostaglandins 1981;21:833–864.
  13. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Perspectives in cancer research. Cancer Res 1992;52:5575–5589.
  14. Tsujii M, Dubois RN: Alternations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493–501.
  15. Tsujii M, Kawano M, Tsuji S, Sawaoka H, Hori M, Dubois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–716.
  16. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schrör K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198–204.
  17. Bennet WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP, Harris CC: p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092–6097.
  18. Subbaramaiah K, Altorki N, Chung WJ, Mastre JR, Sampat A, Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911–10915.
  19. Imamura M, Ohishi K, Mizutani N, Yanagibashi K, Naito M, Shimada Y, Hattori Y, Satomura K, Tobe T: Retrosternal esophagogastrostomy with EEA stapler after subtotal resection of the esophagus: Application and results. Dig Surg 1987;4:101–105.
  20. Okami J, Yamamoto H, Fujiwara M, Tsujie M, Kondo M, Nomura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori S, Monden M: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018–2024.
  21. Krajewska M, Krajewski S, Epstein JL, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, and mcl-l expression in prostate cancers. Am J Pathol 1996;148:1567–1576.
  22. Cagle PT, Brown RW, Lebovitz ML: p53 immunostaining in the differentiation of reactive process from malignancy in pleural biopsy specimens. Hum Pathol 1994;25:443–448.
  23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
  24. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM: Size and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823–4826.
  25. Wilson KT, Fu S, Ramanujuam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929–2934.
  26. Guillem JG, O’Brian CA, Fitzer CJ, Johnson MD, Forde KA, LoGerfo P, Weinstein IB: Studies on protein kinase C and colon carcinogenesis. Arch Surg 1987;122:1475–1478.

    External Resources

  27. Huang XP, Fan XT, Desjeux JF, Castagna M: Bile acids, non-phorbolester-type tumor promoters, stimulate the phosphorylation of protein kinase C substrates in human platelets and colon cell line HT29. Int J Cancer 1992;52:444–450.
  28. Hirano F, Tanada H, Makino Y, Okamoto K, Hiramoto M, Handa H, Makino I: Induction of the transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acid. Carcinogenesis 1996;17:427–433.
  29. Zhang F, Subbaramaiah K, Altorki K, Dannenberg AJ: Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998;23:2424–2428.

    External Resources

  30. Kuylenstierna R, Munck-Wikland E: Esophagitis and cancer of the esophagus. Cancer 1985;56:837–839.

    External Resources

  31. Rubio CA, Aberg B: Barrett’s mucosa in conjunction with squamous carcinoma of the esophagus. Cancer 1991;68:583–586.
  32. Ribet ME, Mensier EA: Reflux esophagitis and carcinoma. Surg Gynecol Obstet 1992;175:121–125.
  33. Pera M, Grande L, Gelabert M, Figueras X, Pera M, Palacin A, Elena M, Cardesa A, Tiburcio AF, Trastek VF: Epithelial cell hyperproliferation after biliopancreatic reflux into the esophagus of rats. Ann Thorac Surg 1998;65:779–786.

    External Resources

  34. Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I: Reflux of duodenal or gastro-duodenal content induces oesophageal carcinoma in rats. Int J Cancer 1996;67:269–274.
  35. Ottignon Y, Deschamps JP: Gas chromatographic/mass spectrometric quantitative analysis of eicosanoids in human oesophageal mucosa. Biomed Environ Mass Spectrom 1988;16:299–304.

    External Resources

  36. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinoma. Cancer Res 1998;58:3761–3776.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50